Cilta-cel 峰值水平的迅速扩增预示着复发/难治性多发性骨髓瘤患者会出现迟发性神经毒性：临床与转化视角
Posted inClinical Updates Hematology-Oncology news

Rapid Peak Cilta-Cel Expansion Predicts Delayed Neurotoxicity in Relapsed/Refractory Multiple Myeloma: Clinical and Translational Insights

Rapid and excessive expansion of ciltacabtagene autoleucel (cilta-cel) CAR T-cells associates with delayed neurotoxicity in relapsed/refractory multiple myeloma, with absolute lymphocyte count serving as a practical biomarker to guide early risk stratification and management.
Optimizing Bridging Therapy Before BCMA-Directed CAR T-Cell Treatment in Relapsed/Refractory Multiple Myeloma: A Real-World Multicenter Analysis
Posted inHematology-Oncology news

Optimizing Bridging Therapy Before BCMA-Directed CAR T-Cell Treatment in Relapsed/Refractory Multiple Myeloma: A Real-World Multicenter Analysis

Bridging therapy before BCMA-directed CAR T-cell infusion in relapsed/refractory multiple myeloma impacts disease control and outcomes. This study analyzes regimen efficacy and safety in 399 patients, highlighting variable responses and safety profiles tied to disease burden and biological risk.
Long-Term Survival Benefit of Daratumumab with Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Insights from the MAIA Final Analysis
Posted inHematology-Oncology news Oncology

Long-Term Survival Benefit of Daratumumab with Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Insights from the MAIA Final Analysis

The MAIA final analysis establishes daratumumab plus lenalidomide/dexamethasone as a superior frontline regimen, significantly extending median overall survival to 7.5 years in transplant-ineligible newly diagnosed multiple myeloma patients.